Clinical Trial

A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 2, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Flotufolastat F-18 Injection is a positron emission tomography (PET) imaging tracer that targets the extracellular domain of prostate-specific membrane antigen (PSMA). This phase I study investigated the safety, biodistribution, radiation dosimetry and Pharmacokinetics of Flotufolastat F-18 Injection in 6 healthy elderly Chinese volunteers.
Trial Details
NCT Number NCT07149831
Lead Sponsor Sinotau Pharmaceutical Group
Conditions Prostate Cancer
Enrollment 6 participants
Start Date 2025-06-07
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-02